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In 2012, everyone was talking about it-the fungal meningitis outbreak that was eventually traced back to 3 lots of methylprednisolone created and sold by the New England Compounding Center (NECC), a compounding pharmacy in Framingham, Massachusetts. By March of 2013, over 40 people had died and over 700 ongoing cases were being tracked.
Reactions to the outbreak were mixed. The issue was in the news daily. Some people were scared. Others were outraged. Most people were asking, ''How could this possibly happen?'' Most people with whom I spoke about the disaster did not understand what pharmaceutical compounding was, the situations under which compounding occurred, and what the benefits and risks were. Furthermore, none of those people had been aware that well over 100 patients who received medications compounded by pharmacies had been injured or killed since 1990, prior to the NECC disaster.
The US FDA has defined traditional pharmacy compounding as ''the combining or altering of ingredients by a licensed pharmacist, in response to a licensed practitioner's prescription for an individual patient, which produces a medication tailored to that patient's special medical needs.'' 1 Traditional pharmaceutical compounding can be traced back to the origins of man. Evidence from archaeology suggests that concoctions were prepared to treat injury and disease during prehistoric times. The Greeks and ancient Romans are believed to have used a variety of medicines compounded by healers. 2 In America, it was commonplace for physicians to compound their own drugs for treatment of the ill and infirm during early colonial times. It was not until 1752, when Johnathan Roberts set up the first hospital pharmacy in Philadelphia after a large shipment of drugs was sent from London to the Pennsylvania hospital, that true pharmacy compounding became a reality. 3 Today, physician and pharmacist preparations have largely been replaced by commercial manufacturing processes that are governed by Current Good Manufacturing Practice (cGMP) regulations and have federal and international oversight. However, the practice of compounding continues to provide an important alternative to fit individual patient requirements (eg, allergy to a specific excipient in a marketed product, inability to swallow tablets/capsules). Drug compounding also has a place in early clinical investigations of new chemical entities. Many pharmaceutical companies use compounded drug for their phase 1 clinical trials. This is a cost-effective practice that enables companies to determine the first-in-human characteristics of the product (eg, toxicity, tolerability, pharmacokinetics, and even preliminary efficacy) prior to investing large sums of money to develop the product under cGMP methods.
Although compounding is to be done on a patient-bypatient, prescription-by-prescription basis, legislation in the early 1990s made it possible for pharmacies to engage in ''nontraditional'' compounding. That is, the combining and altering of ingredients to create sterile products in large batches under state pharmacy laws with limited federal (FDA) oversight. i These regulations and the addition of Section 503A to the Federal Food, Drug, and Cosmetic (FD&C) Act allowed compounding pharmacies to expand their market to supply sterile products to hospitals.
In 2012, the NECC disaster triggered legislative change and a push for reform. On November 27, 2013, President Obama signed the Drug Quality and Security Act (DQSA), which contained important provisions relating to the oversight of compounding of human drugs, including voluntary registration. According to the new law under Section 503B, a compounder can register with FDA to become an outsourcing facility and as such must comply with cGMP requirements, will be inspected by FDA according to a risk-based schedule, and must meet certain other conditions, such as reporting adverse events and providing FDA with certain information about the products they compound. At present, registration with FDA as an outsourcing facility is voluntary, and only 66 compounding facilities have done so.
Today, pharmaceutical compounding is not the first story on the national news; however, it remains a very important, complicated, and controversial topic that is worthy of focus in TIRS and in the pharmaceutical industry at large. FDA now has 11 guidances devoted to this topic and has held 3 Pharmaceutical Compounding Advisory Committee meetings to discuss (among other topics) additions and exceptions of specific substances on the 503A and 503B lists under the DQSA. Almost daily, FDA is posting a new 483 letter or announcing a recall of drugs made by compounding facilities. FDA has also created a public website where information about compounding facility inspections, recalls, and other actions is posted (http:// www.fda.gov/Drugs/GuidanceComplianceRegulatoryInforma tion/PharmacyCompounding/ucm339771.htm). The controversy over drug compounding is so heated and the landscape is changing so rapidly that it is impossible to do justice to this topic in a single special section. However, I have tried to begin the discussion with 3 contributions that delve into the what's and why's of pharmaceutical compounding.
In the first article, Dr Cantrell provides a detailed history of pharmaceutical compounding in the United States and outlines the benefits and possible risks of compounding for the American public. She argues that pharmaceutical compounding is a necessary tool for the physician, and that true advancement in ensuring pharmaceutical compounding is safe and effective requires collaboration among key stakeholders-the pharmacy profession, boards of pharmacy, and FDA. In the second article, Dr Palumbo and his colleagues provide a thoughtful and interesting perspective on the utility of and special challenges related to the use of pharmaceutical compounding for drug supply in clinical trials. Perhaps surprising to some, they rightly point out that there are inconsistent and often contradictory federal and state laws related to randomized controlled clinical trials (RCTs) that potentially conflict with state drug compounding requirements. Finally, in her article, Dr Wilson reports on surprising results from an analysis of the number and type of FDA 483 inspection reports received by sterile compounding pharmacies that reside in states with USP <797> compliance requirements versus states that do not require USP <797> compliance.
Pharmaceutical compounding affects all of us-whether you are the patient, the patient advocate, physician, pharmacist, regulator, lawyer, or congressman. In reading these articles, you should gain a high-level perspective-and hopefully form some opinions of your own-on the complex issues related to traditional and nontraditional pharmaceutical compounding. It is my hope that this special section will stimulate additional discussions among DIA members and TIRS readers and ignite passion to join the efforts to solve the problems that we face. However, that is not enough. We need to take action! We need to work together creatively to leverage the utility of pharmaceutical compounding while at the same time addressing the special challenges of compounding to provide the greatest benefit to patients and our industry as a whole.
